Mostrar el registro sencillo del ítem
dc.contributor | Facultad de Veterinaria | es_ES |
dc.contributor.author | Río González, María Luisa del | |
dc.contributor.author | Fernández Renedo, Carlos | |
dc.contributor.author | Chaloin, Olivier | |
dc.contributor.author | Scheu, Stefanie | |
dc.contributor.author | Pfeffer, Klaus | |
dc.contributor.author | Shintani, Yasushi | |
dc.contributor.author | Pérez Simón, José Antonio | |
dc.contributor.author | Schneider, Pascal | |
dc.contributor.author | Rodríguez Barbosa, José Ignacio | |
dc.contributor.other | Sanidad Animal | es_ES |
dc.date | 2016 | |
dc.date.accessioned | 2024-04-18T06:57:05Z | |
dc.date.available | 2024-04-18T06:57:05Z | |
dc.identifier.citation | del Rio, M. L., Fernández Renedo, C., Chaloin, O., Scheu, S., Pfeffer, K., Shintani, Y., Pérez Simón, J.-A., Schneider, P., & Rodríguez Barbosa, J.-I. (2016). Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells. mAbs, 8(3), 478-490. https://doi.org/10.1080/19420862.2015.1132130 | es_ES |
dc.identifier.issn | 1942-0862 | |
dc.identifier.other | https://www.tandfonline.com/doi/full/10.1080/19420862.2015.1132130 | es_ES |
dc.identifier.uri | https://hdl.handle.net/10612/19905 | |
dc.description.abstract | [EN] Tumor necrosis factor (TNF)/TNF receptor (TNFR) superfamily members play essential roles in the development of the different phases of the immune response. Mouse LIGHT (TNFSF14) is a type II transmembrane protein with a C-terminus extracellular TNF homology domain (THD) that assembles in homotrimers and regulates the course of the immune responses by signaling through 2 receptors, the herpes virus entry mediator (HVEM, TNFSFR14) and the lymphotoxin β receptor (LTβR, TNFSFR3). LIGHT is a membrane-bound protein transiently expressed on activated T cells, natural killer (NK) cells and immature dendritic cells that can be proteolytically cleaved by a metalloprotease and released to the extracellular milieu. The immunotherapeutic potential of LIGHT blockade was evaluated in vivo. Administration of an antagonist of LIGHT interaction with its receptors attenuated the course of graft-versus-host reaction and recapitulated the reduced cytotoxic activity of LIGHT-deficient T cells adoptively transferred into non-irradiated semiallogeneic recipients. The lack of LIGHT expression on donor T cells or blockade of LIGHT interaction with its receptors slowed down the rate of T cell proliferation and decreased the frequency of precursor alloreactive T cells, retarding T cell differentiation toward effector T cells. The blockade of LIGHT/LTβR/HVEM pathway was associated with delayed downregulation of interleukin-7Rα and delayed upregulation of inducible costimulatory molecule expression on donor alloreactive CD8 T cells that are typical features of impaired T cell differentiation. These results expose the relevance of LIGHT/LTβR/HVEM interaction for the potential therapeutic control of the allogeneic immune responses mediated by alloreactive CD8 T cells that can contribute to prolong allograft survival. | es_ES |
dc.language | eng | es_ES |
dc.publisher | Taylor and Francis Group | es_ES |
dc.rights | Atribución-NoComercial 3.0 Internacional | * |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/3.0/ | * |
dc.subject | Inmunología | es_ES |
dc.subject | Sanidad animal | es_ES |
dc.subject.other | Alloreactivity | es_ES |
dc.subject.other | Co-stimulation | es_ES |
dc.subject.other | Cytotoxicity | es_ES |
dc.subject.other | DcR3 (TNFRSF6b) | es_ES |
dc.subject.other | Graft rejection | es_ES |
dc.subject.other | Graft-vs.-host disease | es_ES |
dc.subject.other | HVEM (TNFRSF14; CD270) | es_ES |
dc.subject.other | LIGHT (TNFSF14; CD258) | es_ES |
dc.subject.other | LTβR (TNFRSF3) | es_ES |
dc.subject.other | Transplantation | es_ES |
dc.title | Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | 10.1080/19420862.2015.1132130 | |
dc.description.peerreviewed | SI | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO/Programa Estatal de I+D+I Orientada a los Retos de la Sociedad/PI13/00029 /ES/ Estudio de la interacción CD160/HVEM como diana para el control del rechazo mediado por linfocitos T CD8 y células NK en un biomodelo preclínico de aloreactividad// | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/Junta de Castilla y León/ / LE093U13/ES/ ESTUDIO DE LAS INTERACCIONES DE CD160 CON SU RECEPTOR HVEM EN UN MODELO PRECLÍNICO DE ALOREACTIVIDAD QUE MIMETIZA LA ENFERMEDAD DE INJERTO FRENTE A HUÉSPED EN TRASPLANTE// | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/MINECO/Acción Estratégica de Salud/CP12/03063/ES/CP12/03063/ / | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.essn | 1942-0870 | |
dc.journal.title | mAbs | es_ES |
dc.volume.number | 8 | es_ES |
dc.issue.number | 3 | es_ES |
dc.page.initial | 478 | es_ES |
dc.page.final | 490 | es_ES |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |
dc.subject.unesco | 3109.03 Inmunología | es_ES |
dc.subject.unesco | 2412 Inmunología | es_ES |
dc.description.project | This work has been supported by grants of the Spanish Ministry of Health (Fondo de Investigaciones Sanitarias, PI13/00029), Department of Education of Castilla and Leon Regional Government (Grant# LE093U13) and Mutua Madrile~na Foundation (Basic research grants 2012) to J.I.R.B; by Miguel Servet National Grant (Health National Organization Research Program) CP12/03063 and by Gerencia Regional de Salud GRS963/A/2014 and GRS1142/A/2015 to M.L.R.G; and by the Swiss National Science Foundation to PS. | es_ES |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos [5590]